A quick ride on the M&A train, AstraZeneca bets $100M in cash on T cell engager – Endpoints News

On Tuesday, June 14, John Carroll EIC News EIC sat down with a group of biotech executives to discuss the bear market for industry stocks and how they were coping with it. Here’s the conversation slightly edited for brevity.

Sponsor Martin Mason’s opening:

Thank you John. Welcome everyone. My name is Martin Mason, I’m the CEO of Fujifilm Diosynth. For those of you who don’t know Fujifilm Diosynth, we develop a range of clinical and commercial products, have facilities in Europe and the United States, and approximately 4,000 employees. We run an average of about 150 programs, so when it comes to managing in turbulent times over the past two years, we have a lot of experience with that. Not just keeping commercial pipelines open, but also our response to the pandemic and the particles we’ve had there. One phrase I probably coined about a year ago when we were talking at JP Morgan, is that I talked about managing bad times. Well, it became a fact that we don’t manage and lead these times, we manage them, and that’s really why that’s the purpose and theme we have today.

Premium subscription required

Open this article along with other benefits by subscribing to one of our paid plans.

See also  November jobs report details: Which industries hired the most workers?

Leave a Reply

Your email address will not be published.